HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- ((2S,3S)- 4,4- difluoro- 3- hydroxy- 1- (hydroxyamino)- 3- methyl- 1- oxobutan- 2- yl)- 4- ((4- (morpholinomethyl)phenyl)ethynyl)benzamide

inhibitor of LpxC, an essential enzyme in the biosynthesis of the lipid A component of the outer membrane of Gram-negative bacteria

Also Known As:

LPC-069

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lee, Chul-Jin: 1 article (01/2017)
2.	Lemaître, Nadine: 1 article (01/2017)
3.	Leteurtre, Emmanuelle: 1 article (01/2017)
4.	Liang, Xiaofei: 1 article (01/2017)
5.	Najeeb, Javaria: 1 article (01/2017)
6.	Sebbane, Florent: 1 article (01/2017)
7.	Simonet, Michel: 1 article (01/2017)
8.	Titecat, Marie: 1 article (01/2017)
9.	Toone, Eric J: 1 article (01/2017)
10.	Zhou, Pei: 1 article (01/2017)

Related Diseases

1.	Plague (Bubonic Plague) 01/01/2017 - "Furthermore, LPC-069 is curative in a murine model of one of the most severe human diseases, bubonic plague, which is caused by the Gram-negative bacterium Yersinia pestis Our results demonstrate the safety and efficacy of LpxC inhibitors as a new class of antibiotic against fatal infections caused by extremely virulent pathogens. "
2.	Infections 01/01/2017 - "Furthermore, LPC-069 is curative in a murine model of one of the most severe human diseases, bubonic plague, which is caused by the Gram-negative bacterium Yersinia pestis Our results demonstrate the safety and efficacy of LpxC inhibitors as a new class of antibiotic against fatal infections caused by extremely virulent pathogens. "
3.	Cross Infection (Nosocomial Infection) 01/01/2017 - "The compound LPC-069 has no known adverse effects in mice and is effective in vitro against a broad panel of Gram-negative clinical isolates, including several multiresistant and extremely drug-resistant strains involved in nosocomial infections. "

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)